Arsalan Seyedi, Fereshteh Yazdanpanah, Stephen J Hunt
{"title":"PET-CT in the Management of Metastatic Neuroendocrine Tumors by Interventional Oncology.","authors":"Arsalan Seyedi, Fereshteh Yazdanpanah, Stephen J Hunt","doi":"10.1016/j.cpet.2025.08.003","DOIUrl":null,"url":null,"abstract":"<p><p>This article highlights the role of PET-computed tomography (CT) imaging in diagnosing and managing metastatic neuroendocrine tumors (mNETs). PET-CT, particularly with Gallium-68-DOTATATE, allows earlier and more precise detection of lesions compared to conventional imaging. It identifies somatostatin receptor-positive tumors, aiding in staging, interventional procedures, and guiding peptide receptor radionuclide therapy. The complementary use of fluorodeoxyglucose-PET for predicting tumor biology and managing aggressive, poorly differentiated tumors, helps provide a comprehensive framework for personalized mNETs management. Finally, PET-CT's role in patient diagnosis, staging, surveillance, and management by the interventional oncologist is outlined in detail.</p>","PeriodicalId":94168,"journal":{"name":"PET clinics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PET clinics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.cpet.2025.08.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This article highlights the role of PET-computed tomography (CT) imaging in diagnosing and managing metastatic neuroendocrine tumors (mNETs). PET-CT, particularly with Gallium-68-DOTATATE, allows earlier and more precise detection of lesions compared to conventional imaging. It identifies somatostatin receptor-positive tumors, aiding in staging, interventional procedures, and guiding peptide receptor radionuclide therapy. The complementary use of fluorodeoxyglucose-PET for predicting tumor biology and managing aggressive, poorly differentiated tumors, helps provide a comprehensive framework for personalized mNETs management. Finally, PET-CT's role in patient diagnosis, staging, surveillance, and management by the interventional oncologist is outlined in detail.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
